

ERRATUM

Open Access



Erratum to: Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

Liang Feng^{1,2†}, Hang-Ping Yao^{1,2†}, Sharad Sharma², Yong-Qing Zhou³, Jianwei Zhou⁴, Ruiwen Zhang⁵ and Ming-Hai Wang^{1,2*}

Erratum

Unfortunately, the original version of this article [1] contained an error. The name of one of the authors, Sharad Sharma, was not included in the author list.

The correct author list and the new “Authors’ contributions” section have been correctly included in full in this erratum and updated in the original article.

Authors’ contributions

LF and HPY contribute equally to this work. LF was involved in preparation of antibody-drug conjugation, some in vitro and in vivo studies related to NSCLC. SS was involved in antibody characterization, some in vitro studies related to breast cancer. HPY and YQZ produced and purified anti-RON antibody, participated in some in vitro experiment, analyzed data, and provided partial funds for this project. JWZ provided experimental design and technical support for some intro experiments. RWZ participated in experimental design for combination study. MHW designed the study, participated in data analysis, wrote the manuscript, and secured the fund for completion of this study. All authors read and approved the final manuscript.

Author details

¹State Key Laboratory for Diagnosis & Treatment of Infectious Diseases and Collaborative Innovation Center for Diagnosis & Treatment of Infectious Diseases, First Hospital of Zhejiang University School of Medicine, Zhejiang, China. ²Department of Biomedical Sciences, Texas Tech University Health Sciences Center School of Pharmacy, 1406 Coulter Street, Suite 1117, Amarillo, TX 79106, USA. ³Department of Neurosurgery, First Hospital of Zhejiang University School of Medicine, Zhejiang, China. ⁴Department of Molecular Cell Biology & Toxicology, Nanjing Medical University School of Public Health, Jiangsu, China. ⁵Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, TX, USA.

Received: 25 May 2016 Accepted: 25 May 2016

Published online: 17 June 2016

* Correspondence: minghai.wang@ttuhsc.edu

[†]Equal contributors

¹State Key Laboratory for Diagnosis & Treatment of Infectious Diseases and Collaborative Innovation Center for Diagnosis & Treatment of Infectious Diseases, First Hospital of Zhejiang University School of Medicine, Zhejiang, China

²Department of Biomedical Sciences, Texas Tech University Health Sciences Center School of Pharmacy, 1406 Coulter Street, Suite 1117, Amarillo, TX 79106, USA

References

1. Feng L, Yao HP, Sharma S, Zhou YQ, Zhou J, Zhang R, et al. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. *J Exp Clin Cancer Res.* 2016;35(1):70. doi:10.1186/s13046-016-0347-6.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit



© 2016 The Author(s). **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.